Achaogen, Inc

Alexza Pharmaceuticals is a pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The company's technology, the Staccato system, vaporizes unformulated drug compound to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience. Alexza Pharmaceuticals has four product candidates in clinical development: AZ-001 (Staccato prochlorperazine) for the treatment of acute migraine headaches; AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks associated with panic disorder; AZ-004 (Staccato loxapine) for the treatment of acute agitation in patients with schizophrenia; and AZ-003 (Staccato fentanyl) for the treatment of patients with acute pain. Alexza Pharmaceuticals is located in Palo Alto, Calif.

Ultragenyx Pharmaceutical Inc, based in Novato, is at the forefront of rare disease medicine, dedicated to advancing the rare disease community. With a commitment to progress and innovation, Ultragenyx is shaping the future of healthcare for those with rare diseases. Driven by a mission to propel the rare disease field forward, Ultragenyx Pharmaceutical Inc is a leader in developing treatments and therapies for those in need. Their focus on rare diseases underscores their dedication to improving the lives of patients and caregivers worldwide. Generated from their website's infomation

Portola Pharmaceuticals is a Bay Area–based pharmaceuticals company with a focus on bioresearch and drug development. Their efforts are directed towards global markets, specifically in the treatment of cardiovascular disease and inflammation. Generated from their available business information